Alenia

Alenia Biopharma is a clinical-stage biopharmaceutical company focused on the development of inhaled medicines for the treatment of respiratory diseases, particularly severe asthma and chronic obstructive pulmonary disease (COPD). The company's lead program, ALE-01, is an inhaled p38 mitogen-activated protein kinase (MAPK) inhibitor designed to reduce airway inflammation with high local potency and low systemic exposure. Founded by a team of respiratory experts from academia and the pharmaceutical industry, Alenia aims to provide new therapeutic options for patients who remain symptomatic despite standard-of-care treatments. The company is based in Oxford, UK, and utilizes specialized drug delivery technologies to optimize the efficacy of its respiratory pipeline.